The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)

NCT02273713 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Toxicity

Interventions

DRUG: Nab-paclitaxel

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]